Compare Salesforce Inc (CRM) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Eli Lilly And Co — how do they compare? Salesforce Inc trades at $170.7 (market cap $137.23B), while Eli Lilly And Co trades at $1,146 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 7.5× Salesforce Inc's market cap, and Salesforce Inc pays the higher dividend (1.05%). Which is the better fit depends on your goals.
| CRM | LLY | |
|---|---|---|
Market Cap | $137.23B | $1.03T |
Sector | Technology | Health |
52-Week High | $270.25 | $1.24K |
52-Week Low | $150.12 | $625.65 |
Enterprise Value | $167.28B | $1.07T |
Dividend Yield | 1.05% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.28, showing minimal daily movement (+0.04%) amid recent market volatility. The stock demonstrates strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected) and robust profitability (77.64% gross margin). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while the stock trades near key support at $170. Recent news highlights AI momentum and market concerns about software sector performance.
CRM presents a compelling investment case with strong analyst support (76.84% buy rating) and significant upside to the $235.90 consensus target. However, investors face risks from sector-wide software selloffs, competitive AI landscape pressures, and the stock's 35% YTD decline requiring careful evaluation of growth sustainability versus current valuation discounts.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
